IRX Therapeutics to Present Phase 2 Results at 7th International Conference on Head and Neck Cancer
IRX Therapeutics Names Scott M. Freeman, M.D. Chief Operating Officer
IRX Therapeutics Completes $25 Million Series A Preferred Stock Offering
IRX is pioneering a breakthrough approach to fight cancer and viral disease. The Company’s proprietary technologies stimulate dendritic cells, macrophages, and T-cells by initiating a Th1-specific cellular immune response.
